🇺🇸 Ipratropium/albuterol in United States
1,234 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 1,234
Most-reported reactions
- Pneumonia — 199 reports (16.13%)
- Dyspnoea — 193 reports (15.64%)
- Death — 183 reports (14.83%)
- Fatigue — 134 reports (10.86%)
- Diarrhoea — 103 reports (8.35%)
- Nausea — 94 reports (7.62%)
- Chronic Obstructive Pulmonary Disease — 92 reports (7.46%)
- Asthenia — 82 reports (6.65%)
- Fall — 80 reports (6.48%)
- Headache — 74 reports (6%)
Other Respiratory/Pulmonology approved in United States
Frequently asked questions
Is Ipratropium/albuterol approved in United States?
Ipratropium/albuterol does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Ipratropium/albuterol in United States?
National Jewish Health is the originator. The local marketing authorisation holder may differ — check the official source linked above.